Clinical Trial Update: Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating grazoprevir with peg-interferon and ribavirin for chronic hepatitis C genotype 2 or 3; the study was terminated and results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Grazoprevir (grazoprevir)
• Pegasys (peginterferon alfa-2a) (peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Phase 2 | Status: TERMINATED | Results posted: 2016-03-04